Genetically modified recombinant allergen derivatives designed to reduce allergenic activity induce blocking antibodies that inhibit the binding of allergic patients' IgE antibodies to allergens and hence represent a B cell-based approach to the treatment of allergies [63], [64]. The gene discussed is IGHE; the disease is allergic disease.